Skip to main content
HCPCS Level II/M-Codes/M1482

M1482 HCPCS Level II Code: Positive/detectable hepatitis c virus quantitative or qualitative RNA test result during the denominator identification period

M1482 is the authoritative medical code for Positive/detectable hepatitis c virus quantitative or qualitative RNA test result during the denominator identification period. This classification is used in medical billing and clinical recording to specify the clinical criteria for positive/detectable hepatitis c virus quantitative or qualitative rna test result during the denominator identification period (HCPCS Level II M1482), ensuring healthcare documentation aligns with current federal coding standards.

Billing Status: Processed within HCPCS Level II standards. CMS regulatory guidelines apply.

Medicare Coverage & Payment

  • Medicare coverage: Carrier judgment (CMS coverage code C)
  • Payment category: Service not separately priced (pricing indicator 00)
  • BETOS: Z2
  • Effective: January 1, 2026

Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.

Official Registry Overview & Definition

Positive/detectable hepatitis c virus quantitative or qualitative rna test result during the denominator identification period is a HCPCS Level II code (M1482) for a Medicare-covered supply, service, or procedure. Short description: Pos quan hep c or qual rna.

Nearest Codes in This Family

Official HCPCS Level II classifications closest to M1482 in its code family, with their registry titles.

  • M1477 — Diagnosis of delirium
  • M1478 — Psychoactive substance abuse
  • M1479 — Patients whose functional capacity or motivation (or lack thereof) to improve may impact the accuracy of results of validated tools such as delirium, dementia, intellectual disabilities, and pervasive and specific development disorders
  • M1480 — Patients whose functional capacity or motivation (or lack thereof) to improve may impact the accuracy of results of validated tools such as delirium, dementia, intellectual disabilities, and pervasive and specific development disorders
  • M1481 — Patients receiving hospice or palliative care or who died during the measurement period
  • M1483 — Patients who achieve sustained virological response as identified by an hcv rna test (cpt 87522) or (cpt 87521) with a negative/undetectable hcv rna result that occurred 20 weeks to 12 months after the first positive/detectable hcv rna test result within the denominator identification period
  • M1484 — Patients who did not have a repeat hcv rna labs performed for medical reasons documented by clinician (e.g., patient with limited life expectancy, delay in treatment of hcv related to treatment of hiv, hbv, hepatocellular carcinoma, decompensated cirrhosis)
  • M1485 — Patients who did not achieve sustained virological response as identified by an hcv rna test (cpt 87522) or (cpt 87521) with a negative/undetectable hcv rna result that occurred 20 weeks to 12 months after the first positive/detectable hcv rna test result within the denominator identification period
  • M1486 — Patients admitted to a skilled nursing facility (snf) during the period of evaluation
  • M1487 — Patients in hospice in the year before or during the period of evaluation